Novartis And Tropifexor In NASH, And The Market Assessment [Seeking Alpha]
CONATUS PHARMACEUTICALS INC (CNAT)
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.conatuspharma.com/investor-relations
Company Research
Source: Seeking Alpha
Novartis And Tropifexor In NASH, And The Market Assessment Summary Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019. This week, it focuses on Novartis. Tropifexor is an FXR agonist and lead investigative Phase 2 NASH drug candidate. Interim data readout documented the characteristic adverse events of pruritus and dyslipidemia in some patients. In Q4 2016, Novartis signed a global license agreement with Conatus for the clinical development and commercialization of its lead NASH drug candidate, emricasan, currently in trial for late-phase NASH. At that time, the agreement was perceived by the market as a positive move by Novartis that affirmed its clinical confidence in the therapeutic promise of emricasan. Speculation persists that Novartis could end the agreement. My viewpoint is that a clinical divorce is not happening. Market Assessment Novartis AG ( NVS Novartis could have been at the forefront of NASH therapeutics development
Show less
Read more
Impact Snapshot
Event Time:
CNAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNAT alerts
High impacting CONATUS PHARMACEUTICALS INC news events
Weekly update
A roundup of the hottest topics